Thrombolytic agents in the management of central retinal vein and branch retinal vein occlusion: a review 
Baranov A.Yu., Brzheskiy V.V.

Saint Petersburg State Medical Pediatric University

Central retinal vein and branch retinal vein occlusions are one of the leading causes of refractory vision loss, ranking the second place among retinal vascular disorders. Acute retinal vein occlusive disorders are associated with the thrombosis. Thrombi of the central retinal vein appear similar in composition and origin to other venous thrombi, but there are some differences, caused by the local factors. Pathogenetic treatment of central retinal vein and branch retinal vein occlusions is directed at the blood clot lysis using thrombolytic drugs in order to restore retinal blood flow. Tissue plasminogen activator and prourokinase are commonly used for this purpose nowadays. Numerous clinical studies have shown the high level of efficacy and safety of this group of medications, but there are some issues of current interest, such as choosing the specific drug, the dose, the injection method and the period of administration.

Key words: occlusion, central retinal vein, branch retinal vein, thrombosis, thrombolytic agents, prourokinase, tissue plasminogen activator, intraocular injection methods.
For citation: Baranov A.Yu., Brzheskiy V.V. Thrombolytic agents in the management of central retinal vein and branch retinal vein occlusion: a review // RMJ. Clinical ophthalmology. 2017. № 4. P. 239– 243.